COMSX | GABTX | COMSX / GABTX | |
Total Expense Ratio | N/A | N/A | - |
Annual Report Gross Expense Ratio | N/A | N/A | - |
Fund Existence | 2 years | 31 years | - |
Gain YTD | 36.963 | 22.859 | 162% |
Front Load | N/A | N/A | - |
Min. Initial Investment | 2500 | 1000 | 250% |
Min. Initial Investment IRA | N/A | 250 | - |
Net Assets | 114M | 66.4M | 172% |
Annual Yield % from dividends | 0.00 | 0.30 | - |
Returns for 1 year | 37.20 | 23.59 | 158% |
Returns for 3 years | N/A | 5.40 | - |
Returns for 5 years | N/A | 20.78 | - |
Returns for 10 years | N/A | 4.52 | - |
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
RYOAX | 52.14 | 0.60 | +1.16% |
Rydex Biotechnology H | |||
IVOAX | 18.21 | 0.20 | +1.11% |
Delaware Ivy Mid Cap Income Opps A | |||
GSDPX | 47.44 | 0.48 | +1.02% |
Goldman Sachs US Tax-Managed Eq P | |||
GRHIX | 12.25 | 0.03 | +0.25% |
Goehring & Rozencwajg Resources Instl | |||
VEMIX | 28.06 | -0.16 | -0.56% |
Vanguard Emerging Mkts Stock Idx Instl |